Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
Donovan Mitchell scores 33 points, Cavaliers clinch playoff spot with 129Conservative Christians press Trump to do more on abortionCardinals blow an early 6Max Fried tosses 6 solid innings and Marcell Ozuna homers as Braves beat Marlins 8Forsberg gets 10th career hat trick, sets Nashville scoring record as Predators beat Blackhawks 5Donovan Mitchell scores 33 points, Cavaliers clinch playoff spot with 129Trump’s hush money trial will test Alvin Bragg's efforts at neutrality'HELP' sign on beach points Navy and Coast Guard aviators to men stuck on Pacific atollUS consumer sentiment falls slightly as outlook for inflation worsensElly De La Cruz homers again as the Reds pound the White Sox 11